Moreover, IL-10 is a key regulator of monocyte IL-23 production, providing the basis for targeted therapies such as IL-23p19 and/or IL-1α/IL-1β in IBD patient subgroups (78–80). Here, IL10 is linked to inflammatory bowel disease.